Signed 1st European order! Biosis Healing enters the European market officially with Hernia Graft

by

Referring to Biosis Healing Hernia Graft has, many "titles", it is:

The first key member of Biosis Healing SIS biomaterials series products with independent intellectual property rights

Zhongguancun major product industrialization support project

China's first, and so far, the only animal-derived mesh product holder of the EU CE certification

Up to now, with excellent product quality, it has been selected as the "seeded player" in centralized procurement of six provinces in China

As the "forerunner of SIS material mesh", you will see it in all provinces and cities in the country in addition to the Tibet

However, is not all its glory. In May 2021, the hernia graft had its moment in the spotlight: After receiving the EU CE registration certificate in February 2021, Biosis Healing signed the first order for the herniagraft in Europe in just 3 months. which declared the mesh entry into the European market officially and achieve clinical application in the European hospitals. In the current, the pandemic spreading in European countries,and the sharp decline of hernia surgery, it has achieved the first ice-breaking in the European market.

Entering in the mature European market will not be easy.

Biological mesh is not a new product in the European market, it has been proven safe and effective since the 1980s, and has been widely used in clinical application in Europe. Currently, the market in Europe is dominated by dermal and pericardial matrix cross-linked biological mesh, because of the addition of cross-linking agent, postoperative material degradation in the body of the patient is not ideal. The biodegradable SIS non-crosslinked biological mesh is monopolized by an American company and has been used in Europe for many years at high prices. As the world's second enterprise that has obtained the EU CE registration certificate of SIS non-crosslinked biological mesh, Biosis Healing has attracted great attention from many European distributors since it participated in the German MEDICA exhibition in 2019.

This cooperation agreement was signed by a highly qualified team with 35 years of experience in the sales of biological mesh in the European market. In the severe situation of the pandemic in Europe, it was not easy to promote the cooperation, but the agency's enthusiasm for Biosis Healing into SIS biological mesh did not decrease. After seeing our samples of hernia graft and its practical clinical application in Europe in April this year, the team leader gave great praise to Biosis Healing hernia graft, believing that compared with similar brands in the United States, Biosis Healing products have better clinical application effect and higher cost performance. After we got the EU CE registration certificate, after many in-depth negotiations between the two sides, through the product performance research, as well as the Chinese market in more than two years of ten thousand times of real clinical application effect discussion, the team carefully chose Biosis Healing, and full of confidence signed a 7-year contract covering 7 countries in Southeast Europe.

Biosis Healing has always had a dream of "internationalization", that is to promote the SIS biological mesh products produced by Chinese to the world, and Europe is our first destination. From the day of obtaining the EU CE registration certificate, Biosis Healing marketing team made the arrangement for this moment.

Biosis Healing has the tireless pursuit of research and development of innovation, the uncompromising tempering of product quality and the unchanging positioning of  the brand in the future. Europe's first order gives us great confidence. In addition to our partners this time, agencies in France, Turkey, Greece and other countries are also carrying out clinical application of the product, while agencies in Italy and Switzerland are preparing for government bidding. We believe that “The dream of promoting the SIS biological mesh produced by Chinese to the world" will be achieved in the near future.

About Biosis Healing Hernia Graft:

Biosis Healing hernia graft derived from non-crosslinked extracellular matrix (ECM) with independent intellectual property rights, adopts animal tissue as raw material, removes the risk of immunogenicity, retains natural biological microstructure and growth factors, and can actively induce the regeneration of defective abdominal wall tissue after implantation. No chemical cross-linking agent, with good bioactivity and compatibility, the product can be completely degraded and absorbed, with high mechanical strength, effectively reduce postoperative recurrence and complications. Resistant to infection, it can be used for the repair of infectious abdominal wall tissue. It can be used in various tension-free hernia repair in abdominal surgery to replace the current non-absorbable polymer mesh and effectively avoid the recurrence and complications after the polymer mesh. This product can promote the regeneration and repair of abdominal wall tissue, and has great market potential. In 2018, the company has obtained the China National Medical Products Administration Class III medical devices certificate. At present, the company has entered centralized procurement in six provinces (Yunnan, Guizhou, Chongqing, Henan, Fujian and Shanxi). In 2021, it obtained the EU CE registration certificate, and now it has signed the first order in Europe, and has been applied in some European hospitals.